|Bid||30.71 x 1400|
|Ask||32.71 x 800|
|Day's Range||30.12 - 32.21|
|52 Week Range||15.17 - 34.09|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.20|
ELAN earnings call for the period ending December 31, 2020.
Shares of Elanco Animal Health (NYSE:ELAN) moved higher by 3.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 47.83% over the past year to $0.12, which beat the estimate of $0.09. Revenue of $1,139,700,000 higher by 44.82% year over year, which beat the estimate of $1,060,000,000. Outlook Elanco Animal Health sees Q1 adjusted EPS of $0.20-$0.25. Details Of The Call Date: Feb 24, 2021 View more earnings on ELAN Time: 08:00 AM ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.elanco.com%2F&eventid=2947454&sessionid=1&key=5FB43C4D26A85C954E0546804562785D®Tag=&V2=false&sourcepage=register Technicals 52-week high: $34.09 Company's 52-week low was at $15.17 Price action over last quarter: Up 3.03% Company Overview Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Latin America, and the Asia Pacific with the highest revenue from the North America segment. It offers a range of food animal products used in cattle, sheep, goats, and swine production. See more from BenzingaClick here for options trades from BenzingaRecap: Lowe's Companies Q4 EarningsRecap: Royal Bank of Canada Q1 Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year of 2020, increased guidance for full year 2021, and provided initial guidance for the first quarter of 2021. The results reflect the inclusion of the Bayer Animal Health business that Elanco acquired on August 1, 2020.